Level D· Scientific groundwork from lab and animal studiesAnimal StudyPubMed

The effect of PU/MWCNT nanofiber scaffolds containing hesperidin nanoparticles and mesenchymal stem cells on the microglia and astrocyte phenotype in the spinal cord injury model.

Babaloo H., Barati S., Haghir H., Gholami AA., Moharreri P., Fallahnezhad S.

Animal Study on Spinal Cord Injury, Neuroinflammation, published in Neuroscience (2025) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Animal Study
Journal
Neuroscience (2025)
Country
United States
Reported sample size
—
Source database
PubMed
PMID
40744338
DOI
10.1016/j.neuroscience.2025.07.044
Citations
2

Abstract (original English)

Spinal cord injury (SCI) is a neurodegenerative disease involving inflammation, microgliosis, and astrocytosis. This study examined how polyurethane/multi-walled carbon nanotube (PU/MWCNT) nanofiber scaffolds containing hesperidin nanoparticles (NPs) and adipose-derived mesenchymal stem cells (AMSCs) affect the phenotype of microglia and astrocytes in an SCI model. Thirty-six male rats were divided into six groups: SCI, sham, scaffold, scaffold with AMSCs, scaffold with NPs, and scaffold with AMSCs and NPs. Motor performance in the hind limbs was evaluated using the Basso, Beattie, and Bresnahan (BBB) behavioral test. Tissue sections were prepared and stained with Luxol Fast Blue (LFB) to examine the white matter; Nissl staining was performed to examine neurons. The populations of microglia and astrocytes were assessed using immunofluorescence with Iba-1 and GFAP antibodies, respectively. The expression levels of the A1 (pro-inflammatory) astrocyte gene (C3), the M1 (pro-inflammatory) microglia gene (iNOS), and inflammatory factors, such as IL-1β and TNF-α, were assessed using qRT-PCR. All data were analyzed using SPSS and GraphPad Prism software. Functional evaluation revealed significant behavioral improvement in the group containing a scaffold, AMSCs, and NPs. Nissl and LFB images revealed increased numbers of neurons and remyelination areas in this group, accompanied by dow

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is preclinical work; animal or laboratory results cannot be applied to humans.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence
AnimalsMicrogliaSpinal Cord InjuriesMaleAstrocytesRatsNanoparticlesMesenchymal Stem CellsNanofibersHesperidin

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research